home / stock / howl / howl quote
Last: | $2.90 |
---|---|
Change Percent: | -1.69% |
Open: | $2.95 |
Close: | $2.95 |
High: | $3.07 |
Low: | $2.74 |
Volume: | 159,467 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.9 | $2.95 | $2.95 | $3.07 | $2.74 | 159,467 | 07-17-2024 |
$2.95 | $2.84 | $2.95 | $3.0551 | $2.84 | 238,551 | 07-16-2024 |
$2.86 | $2.69 | $2.86 | $2.89 | $2.67 | 278,061 | 07-15-2024 |
$2.69 | $2.76 | $2.69 | $2.99 | $2.62 | 479,851 | 07-12-2024 |
$2.74 | $2.24 | $2.74 | $2.77 | $2.24 | 583,868 | 07-11-2024 |
$2.2 | $2.33 | $2.2 | $2.35 | $2.18 | 199,725 | 07-10-2024 |
$2.34 | $2.17 | $2.34 | $2.39 | $2.13 | 392,002 | 07-09-2024 |
$2.18 | $2.17 | $2.18 | $2.2899 | $2.01 | 346,128 | 07-08-2024 |
$2.08 | $2.11 | $2.08 | $2.14 | $1.98 | 383,361 | 07-05-2024 |
$2.14 | $2.09 | $2.14 | $2.28 | $2.0101 | 170,573 | 07-04-2024 |
$2.14 | $2.09 | $2.14 | $2.28 | $2.0101 | 170,573 | 07-03-2024 |
$2.06 | $2.32 | $2.06 | $2.32 | $2.04 | 330,740 | 07-02-2024 |
$2.35 | $2.46 | $2.35 | $2.5299 | $2.175 | 432,860 | 07-01-2024 |
$2.44 | $2.47 | $2.44 | $2.7 | $2.34 | 4,306,477 | 06-28-2024 |
$2.51 | $2.31 | $2.51 | $2.73 | $2.31 | 538,356 | 06-27-2024 |
$2.34 | $2.41 | $2.34 | $2.5822 | $2.22 | 446,453 | 06-26-2024 |
$2.34 | $2.72 | $2.34 | $2.72 | $1.96 | 1,008,748 | 06-25-2024 |
$2.61 | $2.86 | $2.61 | $2.9864 | $2.605 | 386,710 | 06-24-2024 |
$2.88 | $2.79 | $2.88 | $3.035 | $2.7 | 334,033 | 06-21-2024 |
$2.69 | $2.9 | $2.69 | $2.985 | $2.61 | 321,821 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Werewolf Therapeutics Inc. Company Name:
HOWL Stock Symbol:
NASDAQ Market:
Werewolf Therapeutics Inc. Website:
- Data demonstrate that administration of WTX-330 reached therapeutically relevant exposure levels of systemically delivered IL-12 prodrug with an improved tolerability profile over historical data for rhIL-12 - - Early WTX-330 dose-escalation data demonstrated encouraging clinical acti...
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...